Adial appoints former Indivior CFO Cary Claiborne to board of directors

ADIAL PHARMACEUTICALS, INC.

Cary J. Claiborne appointed to Adial's board, expanding board to seven members.
He previously served as CFO and board member of Indivior PLC, a specialty pharma company.
Received an option for 60,000 shares at $3.15, vesting monthly over 36 months.
CEO Stilley noted his experience will aid preparations for Phase 3 trial completion and potential commercial launch.
Claiborne's background includes CFO roles at Sucampo Pharmaceuticals and Osiris Therapeutics.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Cary J. Claiborne

director

ADIL · ADIAL PHARMACEUTICALS, INC.

Effective: 2021-11-02
Filed: November 3, 2021, 7:59 PM ET

On November 2, 2021, Cary J. Claiborne joined the board of directors (the “Board”) of Adial Pharmaceuticals, Inc. (the “Company”) to serve as a Class I member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cary J. Claiborne was appointed as director at ADIAL PHARMACEUTICALS, INC..

Action: appointed
Role: director

Exact text from the filing

On November 2, 2021, Cary J. Claiborne joined the board of directors (the “Board”) of Adial Pharmaceuticals, Inc. (the “Company”) to serve as a Class I member of the Board.

View on SEC.gov

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-21-056469

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.